OnKure Therapeutics, Inc. Income Statement
OKUR|1 years of annual SEC 10-K data (FY2024-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
OnKure Therapeutics, Inc. reported $0 in revenue and $35M in net loss for FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.56 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 |
|---|---|
| Revenue | $0 |
| SG&A Expense | $4.8M |
| R&D Expense | $32.1M |
| Operating Income | -$36.9M |
| Interest Expense | $1.6M |
| Net Income | -$35.3M |
| EPS (Basic) | -$124.41 |
| EPS (Diluted) | -$124.41 |
| Shares Outstanding | 283.8K |